438 Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in epidermolysis bullosa patients

Authors :: Albert S. Chiou
M. Joing
Sara Choi
Jean Y. Tang
Shaoying Li
J. Nazaroff
M. Barriga
Y. Dutt-Singkh
Daniel Solis
I. Bailey-Healy
P. Kwon
Source :: Journal of Investigative Dermatology. 138:S74
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: 0301 basic medicine
business.industry
Antagonist
Cell Biology
Dermatology
Pharmacology
medicine.disease
Biochemistry
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Tachykinin receptor 1
Medicine
Epidermolysis bullosa
business
Chronic itch
Molecular Biology

Full Text Access

Tools